Sign In
Buy CPRX
$31.49
+0 (+0%)
At Close: Jul 31, 2026
Catalyst (CPRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
09:30pm, Wednesday, 26'th Feb 2025
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street esti
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates
07:50pm, Wednesday, 26'th Feb 2025
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.53 per share a year ago.
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
04:13pm, Wednesday, 26'th Feb 2025
Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance Q4 2024 Net Product Revenue
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
08:03am, Wednesday, 12'th Feb 2025
CORAL GABLES, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, de
Catalyst Remains a Big Money Favorite
03:56pm, Friday, 07'th Feb 2025
Catalyst Pharmaceuticals, Inc. (CPRX) shares keep gaining on Big Money buys.
This Drug Stock Sits On A Strong Earnings Foundation As It Tests New Entry
08:00am, Friday, 31'st Jan 2025
This pharma stock has made strong gains over the past 12 months thanks to its strong earnings. Now it is testing a fresh buy point.
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
10:55am, Friday, 24'th Jan 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
08:03am, Thursday, 23'rd Jan 2025
CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most S
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:55am, Wednesday, 22'nd Jan 2025
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
08:19am, Tuesday, 21'st Jan 2025
CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, de
Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE
08:30am, Monday, 13'th Jan 2025
Catalyst Pharmaceuticals' investment merits are bolstered by a favorable settlement announced on 01/08/2025. CPRX generates income from three products, primarily FIRDAPSE for LEMS and FYCOMPA for epil
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
10:56am, Thursday, 09'th Jan 2025
Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United States till Feb. 25, 2035.
Here's Why Momentum in Catalyst (CPRX) Should Keep going
10:01am, Thursday, 09'th Jan 2025
Catalyst (CPRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our s
Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?
09:20am, Thursday, 09'th Jan 2025
Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva
02:57pm, Wednesday, 08'th Jan 2025
Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035. The post IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva
